Depression in Huntington's disease

Neuropsychiatric Symptoms of Movement Disorders

Volumn , Issue , 2015, Pages 201-210

  Ossig, Christiana ^a   Storch, Alexander ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84945353011     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-09537-0_9     Document Type: Chapter

References (49)

1. Huntington G. On chorea. Med Surg Rep Phila. 1872;26:317–321.
2. Group Hs DCR. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell. 1993;72(6):971–983. Epub 1993/03/26.
3. Ridley R. M, Frith C. D, Crow T. J, Conneally P. M. An�cipation in Huntington’s disease is inherited through the male line but may onginate in the female. J Med Genet. 1988;25(9):589–595. Epub 1988/09/01.
4. Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M, et al. Trinucleotide repeat length instability and age of onset in Huntington’s disease. Nat Genet. 1993;4(4):387–92. Epub 1993/08/01.
5. Lee J. M, Ramos E. M, Lee J. H, Gillis T, Mysore J. S, Hayden M. R, et al. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology. 2012;78(10):690–695. Epub 2012/02/11.
6. Iizuka R, Hirayama K, Maehara K. A. Dentato-rubro-pallido-luysian atrophy: a clinico- pathological study. J Neurol Neurosurg Psychiatry. 1984;47(12):1288–1298. Epub 1984/12/01.
7. Cardoso F. Differential diagnosis of Huntington’s disease: what the clinician should know. Neurodegener Dis Manag. 2014;4(1):67–72. Epub 2014/03/20.
8. Walker R. H. Update on the Non-Huntington’s disease choreas with comments on the current nomenclature. Tremor Other Hyperkinet Mov (N Y). 2012;2. Epub 2013/02/27.
9. Jung H. H, Danek A, Walker R. H. Neuroacanthocytosis syndromes. Orphanet J Rare Dis. 2011;6:68. Epub 2011/10/27.
10. Harper P. S. The epidemiology of Huntington’s disease. Hum Genet. 1992;89(4):365–376. Epub 1992/06/01.
11. Lovestone S, Hodgson S, Sham P, Differ A. M, Levy R. Familial psychiatric presentation of Huntington’s disease. J Med Genet. 1996;33(2):128–131. Epub 1996/02/01.
12. Beglinger L, Paulsen J. S, Watson D. B, Wang C, Duff K, Langbehn D. R, et al. Obsessive and compulsive symptoms in prediagnosed Huntington’s disease. J Clin Psychiatry. 2008;69(11):1758–1765. Epub 2008/11/18.
13. Van Duijn E, Kingma E. M, Van Der Mast R. C. Psychopathology in verified Huntington’s disease gene carriers, J Neuropsychiatry Clin Neurosci. 2007;19(4):441–448. Epub 2007/12/12.
14. Roos R. A. Huntington’s disease: a clinical review. Orphanet J Rare Dis. 2010;5(1):40. Epub 2010/12/22.
15. Shiwach R. Psychopathology in Huntington’s disease patients. Acta Psychiatr Scand. 1994;90(4):241–246. Epub 1994/10/01.
16. Naarding P, Kremer H. P, Zitman F. G. Huntington’s disease: a review of the literature on prevalence and treatment of neuropsychiatric phenomena. Eur Psychiatry. 2001;16(8):439–445. Epub 2002/01/05.
17. Du X, Pang T. Y, Hannan A. J. A tale of two maladies? Pathogenesis of depression with and without the Huntington’s disease gene mutation. Front Neurol. 2013;4:81. Epub 2013/07/13.
18. Larsson M. U, Luszcz M. A, Bui T. H, Wahlin T. B. Depression and suicidal ideation after predictive testing for Huntington’s disease: atwo-year follow-up study. J Genet Couns. 2006;15(5):361–374. Epub 2006/09/13.
19. Julien C. L, Thompson J. C, Wild S, Yardumian P, Snowden J. S, Turner G, et al. Psychiatric disorders in preclinical Huntington’s disease. J Neurol Neurosurg Psychiatry. 2007;78(9):939–943. Epub 2006/12/21.
20. Koponen S, Taiminen T, Portin R, Himanen L, Isoniemi H, Heinonen H, et al. Axis I and II psychiatric disorders after traumatic brain injury: a 30-year follow-up study. Am J Psychiatry. 2002;159(8):1315–1321. Epub 2002/08/03.
21. Rabins P. V, Pearlson G. D, Aylward E, Kumar A. J, Dowe U. K. Corticalmagnetic resonance imaging changes in elderly inpatients with major depression. Am J Psychiatry. 1991;148(5):617–620. Epub 1991/05/01.
22. Kulisevsky J, Litvan I, Berthier M. L, Pascual-Sedano B, Paulsen J. S, Cummings J. L. Neuropsychiatric assessment of Gilles de la Tourette patients: comparative study with other hyperhnetic and hypokinetic movement disorders. Mov Disord. 2001;16(6):1098–1104. Epub 2001/12/19.
23. Leroi I, O’Hearn E, Marsh L, Lyketsos C. G, Rosenblatt A, Ross C. A, et al. Psychopathology in patients with degenerative cerebellar diseases: a comparison to Huntington’s disease. Am J Psychiatry. 2002;159(8):1306–1314. Epub 2002/08/03.
24. Kessler R. C, Berglund P, Demler O, Jin R, Merikangas K. R, Walters E. E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602. Epub 2005/06/09.
25. Paulsen J. S, Nehl C, Hoth K. F, Kanz J. E, Benjamin M, Conybeare R, et al. Depression and stages of Huntington’s disease. J Neuropsychiatry Clin Neurosci. 2005;17(4):496–502. Epub 2006/01/03.
26. Paulsen J. S, Langbehn D. R, Stout J. C, Aylward E, Ross C. A, Nance M, et al. Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79(8):874–880. Epub 2007/12/22.
27. Ho A. K, Gilbert A. S, Mason S. L, Goodman A. O, Barker R. A. Health-related quality of life in Huntington’s disease: which factors matter most? Mov Disord. 2009;24(4):574–578. Epub 2008/12/20.
28. Murgod U. A, Saleem Q, Anand A, Brahmachari S. K, Jain S, Muthane U. B. A clinical study of patients with genetically confirmed Huntington’s disease from India. J Neurol Sci. 2001;190(1–2):73–78. Epub 2001/09/28.
29. Farrer L. A. Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk. Am J Med Genet. 1986;24(2):305–311. Epub 1986/06/01.
30. Paulsen J. S, Hoth K. F, Nehl C, Stierman L. Critical periods of suicide risk in Huntington’s disease. Am J Psychiatry. 2005;162(4):725–731. Epub 2005/04/01.
31. Levy M. L, Cummings J. L, Fairbanks L. A, Masterman D, Miller B. L, Craig A. H, et al. Apathy is not depression. J Neuropsychiatty Clin Neurosci. 1998;10(3):314–319. Epub 1998/08/26.
32. Naarding P, Janzing J. G, Eling P, Van Der Wer, F. S., Kremer B. Apathy is not depression in Huntington’s disease. J Neuropsychiatry Clin Neurosci. 2009;21(3):266–270. Epub 2009/09/25.
33. Zappacosta B, Monza D, Meoni C, Austoni L, Soliveri P, Gellera C, et al. Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington’s disease. Arch Neurol. 1996;53(6):493–497. Epub 1996/06/01.
34. Nehl C, Ready R. E, Hamilton J, Paulsen J. S. Effects of depression on working memory in presymptomatic Huntington’s disease. J Neuropsychiatry Clin Neurosci. 2001;13(3):342–346. Epub 2001/08/22.
35. Mayberg H. S, Starkstein S. E, Peyser C. E, Brandt J, Dannals R. F, Folstein S. E. Paralimbic frontal lobe hypometabolism in depression associated with Huntington’s disease. Neurology. 1992;42(9):1791–1797. Epub 1992/09/01.
36. Mega M. S, Cummings J. L. Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci. 1994;6(4):358–370. Epub 1994/01/01.
37. Kurlan R, Caine E, Rubin A, Nemeroff C. B, Bissette G, Zaczek R, et al. Cerebrospinal fluid correlates of depression in Huntington’s disease. Arch Neurol. 1988;45(8):881–883. Epub 1988/08/01.
38. Killoran A, Biglan K. M. Therapeutics in Huntington’s disease. Curr Treat Options Neurol. 2012;14:137–149.
39. Marsh L, Mc Donald W. M, Cummings J, Ravina B. Provisional diagnostic criteria for depression in Parhnson’s disease: report of an NINDS/NIMH Work Group. Mov Disord. 2006;21(2):148–158. Epub 2005/10/08/.
40. Mc Allister-Williams R. H. NICE guidelines for the management of depression. Br J Hosp Med (Lond). 2006;67(2):60–61. Epub 2006/02/28.
41. Gelenberg A. J. A review of the current guidelines for depression treatment. J Clin Psychiatry. 2010;71(7):e15. Epub 2010/07/30.
42. Rowe K. C, Paulsen J. S, Langbehn D. R, Wang C, Mills J, Beglinger L. J, et al. Patterns of serotonergic antidepressant usage in prodromal Huntington disease. Psychiatry Res. 2012;196(2–3):309–314. Epub 2012/03/09.
43. Patel S. V, Tariot P. N, Asnis J. L-Deprenyl augmentation of fluoxetine in a patient with Huntington’s disease. Ann Clin Psychiatty. 1996;8(1):234. Epub 1996/03/01.
44. Holl A. K, Wilkinson L, Painold A, Holl E. M, Bonelli R. M. Combating depression in Huntington’s disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol. 2010;25(1):46–50. Epub 2009/12/10.
45. Whittier J, Haydu G, Crawford J. Effect of imipramine (Tofranil) on depression and hyperkinesia in Huntington’s disease. Am J Psychiatry. 1961;118:79. Epub 1961/07/01.
46. Bonelli R. M. Mirtazapine in suicidalHuntington’sdisease. Ann Pharmacother. 2003;37(3):452. Epub 2003/03/18.
47. Squitieri F, Cannella M, Rorcellini A, Brusa L, Simonelli M, Ruggieri S. Short-term effects of olanzapine in Huntington disease. Neuropsychiatr Neuropsychol Behav Neurol. 2001;14(1):69–72. Epub 2001/03/10.
48. Cucsin C, Franco F. B, Fernandez-Robles C, Du Bois C. M, Welch C. A. Rapid improvement of depression and psychotic symptoms in Huntington’s disease: a retrospective chart review of seven patients treated with electroconvulsive therapy. Gen Hosp Psychiatry. 2013;35(6):678. 3–5. Epub 2013/04/02.
49. Piira A, Van Walsem M. R, Mikalsen G, Nilsen K. H, Knutsen S, Frich J. C. Effects of a one year intensive multidisciplinary rehabilitation program for patients with Huntington’s Disease: a prospective intervention study. PLoS Curr. 2013;5. Epub 2014/01/25.